Postprocedural low molecular weight heparin in patients at high risk of subacute stent thrombosis.

摘要: Abstract Background Subacute stent thrombosis (SAT) is a dramatic complication of percutaneous coronary stenting occurring in 0.4–20% cases depending on several angiographic and clinical variables. The role postprocedural low molecular weight heparin (LMWH) preventing early events after high-risk PCI not well established. In this study we describe our experience with LMWH patients deemed to be at high risk SAT. Methods Thirty-six who were treated subcutaneous for least 7 days the intervention identified from database. All cineangiograms charts retrospectively reviewed confirm properties. Thirty-day long-term major adverse (MACEs) documented all patients. Results most common indications deployment ≥3 consecutive stents, presence intracoronary thrombus or ulceration, poststenting residual stenosis, contraindication aspirin thienopyrideines, persistent dissection. majority (61%) had ≥2 factors. Mean treatment period was 12±3 days. At 30 days, none experienced MACE including death, myocardial infarction, repeat revascularization. No bleeding occurred one patient (2.7%) minor bleeding. mean follow-up 31 months, 17% Conclusions Postprocedural safe effective SAT undergoing intervention.